Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;70(9):1399-1407.
doi: 10.1002/art.40508. Epub 2018 Jul 22.

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database

Affiliations
Free PMC article

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database

Megan E B Clowse et al. Arthritis Rheumatol. .
Free PMC article

Abstract

Objective: Anti-tumor necrosis factor (anti-TNF) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti-TNF agents are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF agent approved for the treatment of rheumatic diseases and/or Crohn's disease, has minimal to no active placental transfer. This analysis was undertaken to evaluate pregnancy outcomes in women receiving CZP, especially those exposed during early pregnancy.

Methods: Prospective and retrospective data on maternal CZP exposure were extracted from the UCB Pharma safety database through March 6, 2017. Analysis was limited to prospective reports to avoid potential bias associated with retrospective submissions. The numbers of live births, miscarriages, elective abortions, stillbirths, and major congenital malformations were ascertained.

Results: Of 1,137 prospectively reported pregnancies with maternal exposure to CZP, 528 (including 10 twin pregnancies) had 538 known outcomes: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%). There were 8 major congenital malformations (1.7%) among the 459 infants. First trimester exposure occurred in 367 (81.2%) of 452 pregnancies resulting in 459 live births. Exposure during all 3 trimesters occurred in 201 (44.5%) of 452 pregnancies.

Conclusion: This analysis represents the largest cohort of pregnant women exposed to an anti-TNF agent for management of chronic inflammatory diseases. Analysis of pregnancy outcomes does not indicate a teratogenic effect of CZP, compared to the general population, nor an increased risk of fetal death. The data are reassuring for women of childbearing age considering treatment with CZP.

Figures

Figure 1
Figure 1
Overview of pregnancies exposed to certolizumab pegol (CZP). Eleven patients were included in more than 1 treatment indication category (rheumatic diseases, Crohn's disease, or other) due to multiple reported indications. RA = rheumatoid arthritis; AS = ankylosing spondylitis; axSpA = axial spondyloarthritis; PsA = psoriatic arthritis; JIA = juvenile idiopathic arthritis.
Figure 2
Figure 2
Known outcomes for prospectively reported pregnancies with maternal exposure to certolizumab pegol. Ten twin pregnancies are included in the total number of pregnancy outcomes (4 in mothers with rheumatic diseases, 5 in mothers with Crohn's disease [CD], and 1 in a mother with unknown indication). Miscarriage was defined as embryonic or fetal death before 20 weeks of gestation. Induced abortion includes both elective and medically indicated abortions.
Figure 3
Figure 3
Trimesters of maternal certolizumab pegol (CZP) exposure for prospectively reported pregnancies resulting in a live birth. A, Timing of CZP exposure for all pregnancies. A total of 452 pregnancies resulted in a live birth, including those in which the mother was exposed preconception (n = 5; CZP exposure stopped >14 days and ≤70 days prior to the first trimester) and pregnancies for which the timing of exposure could not be determined (n = 8), as well as 1 patient exposed in the first and third trimesters. Black, dark gray, and light gray shading represent CZP exposure during the first, second, and third trimesters, respectively; shading gradients reflect exposure during multiple trimesters. B, Exposure by indication for CZP use. There were 8 live births for which the timing of exposure could not be determined (n = 2 for patients with rheumatic disease and n = 6 for patients with Crohn's disease).

Comment in

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

References

    1. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken) 2015;67:313–25. - PubMed
    1. Chakravarty E, Clowse ME, Pushparajah DS, Mertens S, Gordon C. Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open 2014;4:e004081. - PMC - PubMed
    1. Van den Brandt S, Zbinden A, Baeten D, Villiger PM, Ostensen M, Forger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 2017;19:64. - PMC - PubMed
    1. Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom study of 209 pregnant women. Aliment Pharmacol Ther 2013;38:501–12. - PubMed
    1. Boyd HA, Basit S, Harpsoe MC, Wohlfahrt J, Jess T. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One 2015;10:e0129567. - PMC - PubMed

Publication types

Feedback